Patents by Inventor Xianxiu QIU

Xianxiu QIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10618939
    Abstract: The present invention relates to a Beclin 1-UVRAG complex structure which reveals a tightly packed coiled coil assembly with Beclin 1 and UVRAG residues complementing each other to form a stable dimeric complex. This potent physical interaction is critical for UVRAG-dependent EGFR degradation but less critical for autophagy. Targeting the Beclin 1 coiled coil domain with rationally designed stapled peptides leads to enhanced autophagy activity and EGFR degradation in non-small cell lung cancer (NSCLC) cell lines, suggesting translational value for these compounds.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: April 14, 2020
    Assignee: The Hong Kong Polytechnic University
    Inventors: Yanxiang Zhao, Shuai Wu, Wenchao Yang, Yunjiao He, Xiaohua Li, Xianxiu Qiu
  • Publication number: 20180208627
    Abstract: The present invention relates to a Beclin 1-UVRAG complex structure which reveals a tightly packed coiled coil assembly with Beclin 1 and UVRAG residues complementing each other to form a stable dimeric complex. This potent physical interaction is critical for UVRAG-dependent EGFR degradation but less critical for autophagy. Targeting the Beclin 1 coiled coil domain with rationally designed stapled peptides leads to enhanced autophagy activity and EGFR degradation in non-small cell lung cancer (NSCLC) cell lines, suggesting translational value for these compounds.
    Type: Application
    Filed: March 14, 2018
    Publication date: July 26, 2018
    Inventors: Yanxiang ZHAO, Shuai WU, Wenchao YANG, Yunjiao HE, Xiaohua LI, Xianxiu QIU
  • Publication number: 20180002381
    Abstract: The present invention relates to a Beclin1-UVRAG complex structure which reveals a tightly packed coiled coil assembly with Beclin 1 and UVRAG residues complementing each other to form a stable dimeric complex. This potent physical interaction is critical for UVRAG-dependent EGFR degradation but less critical for autophagy. Targeting the Beclin coiled coil domain with rationally designed stapled peptides leads to enhanced autophagy activity and EGFR degradation in non-small cell lung cancer (NSCLC) cell lines, suggesting translational value for these compounds.
    Type: Application
    Filed: June 29, 2017
    Publication date: January 4, 2018
    Inventors: Yanxiang ZHAO, Shuai WU, Wenchao YANG, Yunjiao HE, Xiaohua LI, Xianxiu QIU